Video Experimental Relacionado

Updated: Sep 10, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

En vivo el control del crecimiento tumoral por control general No reprimible 2 Agentes de orientación Resultados de

Feven Tameire¹, Paulina Wojnarowicz², Crissy Dudgeon¹

¹HiberCell, Inc., Boston, MA, United States.

Molecular cancer therapeutics

|August 20, 2025

Resumen

Los activadores de GCN2 en dosis bajas, no los inhibidores, reducen el crecimiento tumoral mediante la activación de la respuesta integrada al estrés. Este hallazgo inesperado tiene un impacto en el desarrollo clínico de terapias contra el cáncer dirigidas a GCN2.

Área de la Ciencia:

Biología molecular
Señalización celular
Investigación del cáncer

Sus antecedentes:

Control general La quinasa no reprimible 2 (GCN2) es crucial para la respuesta integrada al estrés (ISR) bajo estrés nutricional.
La inhibición de GCN2 es prometedora para el tratamiento del cáncer al inducir la apoptosis e inhibir el crecimiento tumoral.
Estudios previos sugieren que la inhibición de GCN2 es ineficaz sin estrés nutricional.

Objetivo del estudio:

Investigar el doble papel de los inhibidores del GCN2 en diferentes concentraciones.
Aclarar el mecanismo por el cual los agentes dirigidos al GCN2 afectan la viabilidad y el crecimiento de las células tumorales.
Aclarar el panorama de desarrollo clínico de los compuestos dirigidos al GCN2.

Principales métodos:

Detección de múltiples inhibidores del GCN2 en varias concentraciones.
Ensayos bioquímicos y basados en células para evaluar la actividad del GCN2.
Estudios in vitro e in vivo en los que se utilizaron modelos de nocaut y tratamiento con ISRIB.
Análisis de los marcadores de la apoptosis (caspasa dividida 3, PARP dividido).

Principales resultados:

Los múltiples inhibidores del GCN2 activan el GCN2 en concentraciones bajas e inhiben en concentraciones altas.
La activación de GCN2, no la inhibición, se correlaciona con la disminución de la viabilidad in vitro y la inhibición del crecimiento tumoral in vivo.
La activación ISR dependiente de GCN2 es esencial para los efectos observados, confirmados por el tratamiento ISRIB.
Las dosis activadoras inducen marcadores de apoptosis, mientras que los agentes no activadores no muestran ningún impacto en la viabilidad.

Conclusiones:

La activación de GCN2 por agentes específicos, en lugar de la inhibición, es clave para los efectos antitumorales.
Los hallazgos ponen de relieve la importancia de los efectos dependientes de la concentración para los fármacos dirigidos al GCN2.
Este estudio proporciona información crítica para optimizar las terapias contra el cáncer dirigidas a GCN2.

Más Videos Relacionados

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Videos de Conceptos Relacionados

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...